Women, Hispanic patients, people who have other health problems, and those who have more lymph nodes removed are at higher risk of emergency visits for hypoparathyroidism after thyroid surgery, a study found. “Most risk factors identified are not modifiable, but they help identify high-risk patients who could benefit from…
News
Treatment with the investigational therapy encaleret normalized calcium levels for most people with chronic hypoparathyroidism in a small proof-of-principle study. That’s according to data announced by Bridgebio Pharma, which is developing encaleret with its affiliate Calcilytix Therapeutics. The company said it hopes to launch a clinical trial…
People with long-lasting hypoparathyroidism after thyroid surgery are at risk of having deteriorating kidney function, according to a study from Spain. “This study demonstrated that patients were at greater risk of chronic kidney disease, progression to end-stage kidney disease, and faster decline in [kidney function] compared to subjects without…
Postmenopausal women and men over age 50 with chronic hypoparathyroidism showed signs of significant bone fragility, with a high proportion of fractures and osteoporosis, according to a study that calls for a closer follow-up of patients’ skeletal health. The study, “Skeletal health status among patients with…
Hypoparathyroidism is often temporary in children who undergo surgical removal of the thyroid, or thyroidectomy, with most recovering normal parathyroid function within six months, a study in China shows. The time needed to recover from hypoparathyroidism was found to be closely related to the levels of parathyroid hormone (PTH)…
A Phase 2 clinical trial testing MBX 2109 in people with chronic hypoparathyroidism has finished enrolling participants, according to MBX Biosciences, the treatment’s developer and sponsor of the trial. “Completion of enrollment in our Phase 2 trial in [hypoparathyroidism] marks a significant milestone for MBX and brings us closer…
Yorvipath (palopegteriparatide) has been approved in Australia as a parathyroid hormone (PTH) replacement therapy for adults with chronic hypoparathyroidism. The news follows similar approvals in the European Union in 2023, and in the U.S. last year. Yorvipath will be made available in Australia through Specialised Therapeutics, under…
To help people with hypoparathyroidism in the U.S. who are facing out-of-pocket medical costs, The Assistance Fund (TAF) — a nonprofit launched in 2009 to aid individuals with a range of health conditions — has opened a program for patients and families living with the rare disease. This…
Weekly treatment with MBX 2109, an experimental hormone replacement that MBX Biosciences is developing for chronic hypoparathyroidism, appears to be long-acting and to mimic natural parathyroid hormone (PTH) in healthy adults. Data come from a Phase 1 clinical trial (NCT05158335) where side effects reported with multiple doses…
Note: This story was updated Dec. 16, 2024, to correct errors in terminology from hyperparathyroidism to hypoparathyroidism. Reactive supplement use — giving oral supplements of calcium and vitamin D after total thyroidectomy, or the complete surgical removal of the thyroid gland — is safe and effective in patients experiencing…
Recent Posts
- New weekly therapy moves toward Phase 3 for hypoparathyroidism
- My PATTH with hypoparathyroidism is unknown, but my purpose is clear
- As Tatum’s return from injury shows, a comeback is better than a setback
- Calcium, vitamin D supplements key after thyroid surgery, per study
- An at-home calcium tester is in development — and I’m celebrating!